Antibodies elicited by the first non-viral prophylactic cancer vaccine show tumor-specificity and immunotherapeutic potential

MUC1 is a shared tumor antigen expressed on >80% of human cancers. We completed the first prophylactic cancer vaccine clinical trial based on a non-viral antigen, MUC1, in healthy individuals at-risk for colon cancer. This trial provided a unique source of potentially effective and safe immunothe...

Descripción completa

Detalles Bibliográficos
Autores principales: Lohmueller, Jason J., Sato, Shuji, Popova, Lana, Chu, Isabel M., Tucker, Meghan A., Barberena, Roberto, Innocenti, Gregory M., Cudic, Mare, Ham, James D., Cheung, Wan Cheung, Polakiewicz, Roberto D., Finn, Olivera J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4992835/
https://www.ncbi.nlm.nih.gov/pubmed/27545199
http://dx.doi.org/10.1038/srep31740

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4992835/
https://www.ncbi.nlm.nih.gov/pubmed/27545199
http://dx.doi.org/10.1038/srep31740

Ejemplares similares